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Restless legs syndrome (RLS) is one of the most common neurological disor-
ders. It describes an irresistible urge to move the legs, mostly manifested in
the evening and at night, which can lead to severe sleep disturbance. As part
of the European Brain Council (EBC)-led Value-of-Treatment project, this
study aimed at capturing the socioeconomic impact of RLS related to the
inadequate diagnosis and treatment across different European healthcare set-
tings. The economic burden of RLS was estimated using the published EBC
framework of analysis in three separate European Union healthcare systems
(France, Germany, and Italy). The RLS care pathway was mapped to identify
the unmet needs of patients. Based on specific patient stories, the economic
impact of correctly diagnosing RLS and changing between inadequate and
target treatment was calculated using appropriate scenario analysis. RLS
proved to be a significant personal and social burden, when epidemiological
data, high prevalence of RLS, and its need for treatment are combined. By
looking at the savings emerging from the provision of optimal care manage-
ment (timely and correct diagnosis, evidence-based therapy, avoidance of ther-
apy-related complications such as augmentation), the authors foresee
substantial economic savings with the achievement of adequate diagnosis and
treatment of RLS. Education about RLS is urgently needed for all subspe-
cialties involved in RLS patient care as well as the general public. Equally
important, the search for new causal treatment strategies should be intensified
to reduce suffering and substantial societal cost.
Introduction
Restless legs syndrome (RLS) is a common neurologi-
cal disease that is characterized by an irresistible and
compelling urge to move the legs (or arms and some-
times other body parts as well), usually accompanied
by highly uncomfortable sensations in the affected
limbs [1]. RLS is a common condition that has a sub-
stantial impact on daily activities and quality of life.
The circadian variation of RLS symptoms, with major
complaints in the evening and at night, leads to severe
sleep disturbance and deprivation and has a substan-
tial impact on normal daily activities and the lives of
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sufferers and their families. It influences and interacts
with many comorbidities [2], and it also causes loss of
work, loss of social networks, and even early and pre-
mature retirement.
The diagnosis is primarily set by a clinical history
(essential questions) that can be taken by any physi-
cian independent of the discipline. Misdiagnoses and
none or incorrect treatment regimens occur due to
lack of knowledge and expertise at both the primary
and secondary care levels and, as a consequence, lead
to wrong routing of the patient. As a result, diagnosis
and correct management of RLS is delayed for many
patients. Access to specialized RLS care is rarely
available across Europe. The currently available medi-
cations provide symptom reduction only, and side
effects of the medicines have created new and serious
problems such as augmentation of RLS symptoms
[3,4].
Estimates of the prevalence of RLS have varied
widely, depending on the patient population and the
diagnostic criteria studied. The publication of stan-
dardized criteria for the diagnosis of RLS [1,5] has
facilitated comparisons between studies, yielding reli-
able estimates of the prevalence of RLS in the general
population. Population-based studies using these crite-
ria suggest that RLS symptoms of any frequency or
severity are present in 5% to 10% of the general pop-
ulation in Western industrialized countries [6,7] and in
a lower proportion in Asian populations [8,9].
According to recent data from the Study of Health in
Pomerania study, the prevalence of RLS in the adult
German population is 6% to 9%, including all levels
of severity [10]. In addition, Allen et al [11] report
that about 2.7% of the European population suffer
from moderate to severe RLS. It has been suggested
that RLS with an early onset (before age 45 years)
tends to progress slowly, whereas RLS of later onset
generally progresses rapidly until the severity reaches
a plateau. As a result, the greatest burden of morbid-
ity is seen amongst middle-aged to elderly patients
[12]. A majority of studies have reported that the
prevalence of RLS is approximately twice as high in
women as in men [13], with an increase of prevalence
with age among both genders [13]. In addition, there
is evidence from the Dortmund Health Study in Ger-
many that approximately 1.6% of the population was
both affected by RLS and wished for treatment for
RLS [14]. Given its high prevalence in the general
population and how it affects the patients’ lives, it is
necessary to evaluate the socioeconomic impact of
RLS and the inadequate RLS diagnosis and treatment
across different European Union (EU) healthcare
systems.
The aims of this study were: (i) to present an anal-
ysis of the socioeconomic impact of RLS as a disease
across a series of EU settings, (ii) to describe the
RLS patient’s pathway and key treatment gaps, and
(iii) to evaluate the economic impact of filling the
key treatment gaps identified looking at specific EU
case studies. For each of the three aims, both meth-
ods and key results are reported. The final scope was
to discuss the overall findings of the studies and
report on the policy recommendations emerging from
them, in alignment with the overall European Brain
Council (EBC)-led Value-of-Treatment (VoT) project
[15].
The socioeconomic impact of RLS as a
disease in Europe
Methods
The economic burden of RLS was estimated for the
first time across EU settings by using the published
framework adopted by the EBC in “The Economic
Cost of Brain Disorders in Europe 2010” [16]. The
analysis was performed for three separate healthcare
systems, France, Germany, and Italy, as examples of
EU nations with different healthcare systems with
regard to delivery of services, financing, and cover-
age. Details on the methodology applied are
described elsewhere [16]. One-year prevalence and
annual cost per person of RLS were based on best
estimates derived from the literature reviews by pan-
els of working-group experts [17] and 2016 gross
domestic product per capita (http://www.tradingeco-
nomics.com/) [18,19]). The estimates included health-
care costs as well as indirect costs to society, such as
lost productivity due to reduced ability to work (in-
cluding sick days) or to work at full capacity. The
socioeconomic impact of RLS in France, Germany,
and Italy was provided; the yearly total costs were
presented for the three country settings. Two separate
scenarios were considered. First, we calculated the
economic impact of RLS when assuming a prevalence
of the disease with a treatment wish, equal to 1.6%
[14]. Second, in the next calculation, we considered a
more relaxed scenario with a prevalence of 2.7%
RLS [11].
Results
When considering the overall economic impact of
RLS in the EU sample given by the three countries
(France, Germany, and Italy as pooled data; Fig. 1),
RLS with prevalence 1.6% (scenario 1) reported a
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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total yearly cost of €20,188.68 million (including
€6181.07 million for France, €8339.28 million for Ger-
many, and €5668.33 million for Italy). Costing esti-
mates produced when using different assumption for
RLS prevalence are presented in Fig. 1.
The RLS care pathway and key treatment
gaps
Methods
The RLS care pathway was mapped looking at the
patient experience and treatment gaps to describe
patients’ needs and issues along the whole care process
and identify the critical unmet needs of patients as well
as the underlying causal factors. The results of the anal-
ysis were built based on available evidence-based diag-
nosis and treatment guidelines in Europe [3] as well as
national guidance in France (La Societe Francaise
de Neurologie; http://www.sf-neuro.org/), Germany
(Deutsche Gesellschaft f€ur Neurologie; https://www.dgn.
org/) and Italy (Societa’ Italiana di Neurologia; http://
www.neuro.it/), and expert and patient opinions. The
group set out to identify the typical stages in the patient
journey. Diagnostic delay, access to good care, the cost of
nontreatment, sick leave, loss of income/job, proportion
of drug-resistant patients, awareness of RLS among medi-
cal professionals, available medicines or lack of medicines,
and importantly, incorrect application and dosages that
cause adverse reactions, possible prevention, screening/
prodroma, early intervention, and overall disease manage-
ment were all mapped using the framework provided by
the EBC (Fig. 2). Recommendations were proposed on
how these shortcomings can be improved.
Three experts, one for each country (Y.D. for
France, C.T. for Germany, R.F. for Italy), considered
a specific treatment gap emerging from the care path-
way analyses and individually selected a typical
patient story that would describe the impact of subop-
timal treatment in the patient’s life. Each case of sub-
optimal treatment (baseline scenario) was then
matched with a target scenario to describe what would
happen to the same patient in case that patient
received appropriate care.
Results
The major gaps identified alongside the patient path-
way included delayed diagnosis, insufficient response,
and augmentation as a result of treatment complica-
tion. They were described in terms of typical patient
cases.
Augmentation is a severe adverse reaction of long-
term dopaminergic therapy of RLS [20]. With high
doses of levodopa/dopamine decarboxylase inhibitor
or dopamine agonists, RLS symptoms become much
worse and spread over the entire body during many
hours per day. A significant aspect of augmentation is
often a misinterpretation of this phenomenon: when
symptoms get worse, the treating physician will
assume loss of efficacy and increase the dosage. This
results in even more severe augmentation. More is not
better in RLS treatment. As a result, a drug holiday is









Italy Germany France Pooled data from
the three countries
Scenario 1: RLS prevalence 1.6% Scenario 2: RLS prevalence 2.7%
Figure 1 Socioeconomic impact of restless legs syndrome (RLS) in France, Germany, and Italy. Yearly total costs according to differ-
ent prevalence assumptions are presented for the three country settings (millions euros, 2016). Scenario 1 relates to the prevalence of
RLS patients who wish therapy in a city in Germany [14]. Scenario 2 relates to the overall prevalence of RLS in the United States
from Allenet al[11].
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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patient due to extreme withdrawal symptoms and no
sleep for many days.
The economic impact of closing the key
treatment gaps
Methods
The analyses for the VoT project were built on previ-
ously published research in the field, particularly
where it generated evidence on effectiveness, and used
methods successfully employed in published studies to
explore the economic case for closing treatment gaps
in brain disorders. Depending the quality and type of
the evidence available, economic modeling techniques
were used to build a series of analytical models to
evaluate the cost-effectiveness of closing the treatment
gap and explore the impact of transitioning from sub-
optimal patient pathway to what can be considered as
target treatment according to clinical guidance [15]. In
Figure 2 Measuring value in healthcare by achieved outcomes, starting with defining the patient’s needs (inpatient care pathway; from
the European Brain Council, 2017).
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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the case of RLS, only a single article [17]—an out-
patient scenario in Germany—on the economic evi-
dence was available, and effectiveness data were
very limited. Given the challenges experienced in
sourcing relevant evidence to populate the economic
modeling framework (EBC, 2017), the working
group agreed to consider a scenario analysis using
three typical patients to illustrate cases of subopti-
mal treatment as presented by the care pathway
analyses. The three country experts (Y.D., C.T., and
R.F.) gathered their personal opinions on the use of
resources in the different scenarios and provided a
source of unit cost from their local country’s public
tariff and their personal practice data. Costs related
to absenteeism from work were calculated looking
at country wages for the specific case-study jobs.
The timeframe varied according to the personal life
story described in the three case studies. Cost esti-
mates included those for the one person described
in the case study and covered those incurred by the
healthcare provider or society, depending on the
individual cases. A discount rate of 3.5% was
applied as appropriate. Details on the assumptions
made as well as the unit costs and sources of infor-
mation across country settings are reported in
Tables 1 to 4.
For the purpose of our sensitivity analyses we
assumed one polysomnography (PSG) outpatient pro-
cedure and zero MRI. We consider four different
options for PSG outpatient procedure costs (10%,
20%, 30%, 100%). The overall cost estimates for the
worst case management remain unchanged. The total
saving for healthcare related costs (compared with
worst case management) are reported below.
Results
The case reports on the economic savings across
healthcare systems were detailed when closing the
three treatment gaps illustrated by the typical
patients’ stories. The economic savings were calculated
when changing from suboptimal to target treatment
(Fig. 3).
Delayed diagnosis
When calculating the difference in direct costs for the
healthcare provider, adequate treatment provides a
cost savings of €1600 to €33,300 over a period of
54 years across the three healthcare systems. When
healthcare and productivity costs incurred by the
whole society are considered, adequate treatment pro-
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Insufficient response
On an 11-year time horizon, adequate treatment
brings a cost saving of €3600 to €7800 per patient
case.
Augmentation
When calculating the difference in indirect costs for
the healthcare provider, adequate treatment would
provide a cost savings of €8900 to €36,000 euros per
patient case in a 4-year time horizon. The variation in
estimates across the three countries may be attributa-
ble to differences in health delivery practices, cover-
age, and care payment systems.
Estimates on the savings per country are reported
in Figure 3. More details on the total costs attached
to the baseline and target scenarios for the three
patients’ stories are reported in Tables 1 to 4.
Discussion
For the first time, results from our cost of illness anal-
ysis on RLS, based on the robust framework devel-
oped as part of the EBC 2010 report [16], allowed us
to provide the economic impact of RLS with specific
application to a selection of EU healthcare systems.
The study presents not only differences with respect to
their financing and service provision arrangements, but
also with respect to the underlying governance mecha-
nisms. It showed that RLS economic impact varies
between €20,188.68 million per year, when the preva-
lence of RLS patients wishing for treatment is assumed
to be 1.6% of the population, to €34,068.41 million
per year, when the prevalence of RLS patients is
assumed to be 2.7% of the population for the three




€ - € 20,000 € 40,000 € 60,000 
Total costs - Healthcare system perspecve
Total costs - Societal perspecve
Total costs - Healthcare system perspecve
Total costs - Societal perspecve
Total costs - Healthcare system perspecve










€ - € 20,000 € 40,000 € 60,000 
Total costs - Healthcare system perspecve
Total costs -healthcare and paent medicine
costs
Total costs - Healthcare system perspecve










€ - € 20,000 € 40,000 € 60,000 
Total costs - Healthcare system perspecve
Total costs -healthcare and paent medicine
costs
Total costs - Healthcare system perspecve










Figure 3 Economic savings when closing restless legs syndrome (RLS) treatment gaps (changing from inadequate to target treatment).
Total period of time covered in the modeling: 56 years (delayed diagnosis), 11 years (insufficient response), and 4 years (augmenta-
tion). The perspectives adopted were as follows: France—The healthcare costs incurred by the healthcare system include visits, hospital
stays, and tests, as there is no reimbursement of any RLS medicine (neither dopa agonist nor oxycodone–naloxone). The healthcare
costs incurred by the society cover all patient costs for medicines plus healthcare costs incurred by the healthcare system (i.e., visits,
hospital stays, and tests). In addition, we included the productivity loss (due to absenteeism from work). Germany and Italy—The
healthcare costs incurred by the healthcare system include visits, hospital stays, tests, and RLS medicines. In the two countries the
societal perspectives include both the healthcare costs covered by the national healthcare system (i.e., visits, hospital stays, tests, and
RLS medicines), plus the productivity loss (due to absenteeism from work). GP, general practitioner.
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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Due to delayed diagnosis and inadequate treatment,
RLS cases resulted in severe treatment complications
with significant impact on both direct and indirect
healthcare costs. When considering closing current
treatment gaps with a change from suboptimal (in
terms of delayed diagnosis, insufficient response, or
augmentation) to optimal care, we confirmed substan-
tial economic savings with the achievement of ade-
quate diagnosis and treatment of RLS. Crucially, the
RLS epidemiological studies define RLS only accord-
ing to a three-question set used in epidemiological sur-
veys [11,13,21,22], but not along the need of treatment,
and therefore our estimates should be considered a
rough estimate of the overall RLS impact. The wish
for treatment is an essential driver of costs in RLS [14]
as well as severity of the disease [17].
This study offers also a first attempt at measuring the
economic benefits of addressing three major treatment
gaps in RLS care pathways looking into a selection of
real case studies. Economic case study analyses are
increasingly widely used to contribute to an early assess-
ment of the economic case for specific interventions/ser-
vices where there is a lack of evidence of the wider
impacts in the literature and no economic and epidemio-
logical data are available to build appropriate economic
modeling. Economic cases have already been used to
inform health policy, and practical examples can be
found elsewhere with application to a series of long-term
conditions and multiple comorbidities ([23]; National
Health Service England, 2017).
There are several limitations of the current case stud-
ies: the three cases have been selected by RLS experts
arbitrarily, no formal selection process has been used,
and they are single cases following individual treatment
models or failures of these, although experts were
advised to select typical, characteristic, and frequently
occurring cases. Sources on the three different countries
varied across the three cases, and different perspectives
were adopted depending on the type of resources. There-
fore, the economic data produced by the case study anal-
yses can only be examples for the single country and the
individual expert. The calculated costs are based on the
assumption that 100% of RLS patients undergo an
inpatient hospital stay, polysomnographic diagnostic
procedure, and an MRI. The authors, however, do not
by any means imply that every RLS patient may need
polysomnography and/or diagnostic magnetic reso-
nance imaging. For the respective calculations assuming
that only a small proportion (10%–30%) of RLS
patients receive these investigations, we refer to the foot-
notes of Tables 1, 2 and 3.
When translating RLS costs and the consequences
of RLS inadequate treatment, to the general popula-
tion we foresee substantial economic impacts well
beyond what may be anticipated from current epi-
demiological figures in the literature. Unfortunately,
the economic evidence, deriving from both the cost of
illness and cases studies analyses, is limited to three
specific EU settings. More quality data and random-
ized case studies should be performed to map the
impact of RLS across multiple countries, including
both developed and emerging national economies.
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